-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, CsWVXGuXvVFaD9mb1uFgp1qTSXazPqhTmo+Ug3hFEbeMQKOqusR53E9nDbKrIRSc sc/cfRHUQvxjn4aozs0r1Q== 0001047469-06-001946.txt : 20060214 0001047469-06-001946.hdr.sgml : 20060214 20060214133726 ACCESSION NUMBER: 0001047469-06-001946 CONFORMED SUBMISSION TYPE: 13F-HR PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20051231 FILED AS OF DATE: 20060214 DATE AS OF CHANGE: 20060214 EFFECTIVENESS DATE: 20060214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Hambrecht & Quist Capital Management LLC CENTRAL INDEX KEY: 0001300336 IRS NUMBER: 010628853 STATE OF INCORPORATION: DE FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 13F-HR SEC ACT: 1934 Act SEC FILE NUMBER: 028-10950 FILM NUMBER: 06611828 BUSINESS ADDRESS: STREET 1: 30 ROWES WHARF CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 617 772-8500 MAIL ADDRESS: STREET 1: 30 ROWES WHARF CITY: BOSTON STATE: MA ZIP: 02110 13F-HR 1 a2167427z13f-hr.txt 13F-HR UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 13F FORM 13F COVER PAGE Report for the Calendar Year or Quarter Ended: December 31, 2005 ----------------------- Check Here if Amendment / /; Amendment Number: --------- This Amendment (Check only one.): / / is a restatement. / / adds new holdings entries. Institutional Investment Manager Filing this Report: Name: Hambrecht & Quist Capital Management LLC ---------------------------------------- Address: 30 Rowes Wharf, 4th Floor ---------------------------------------- Boston, MA 02110-3328 ---------------------------------------- Form 13F File Number: 28- --------------------- The institutional investment manager filing this report and the person by whom it is signed hereby represent that the person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables, are considered integral parts of this form. Person Signing this Report on Behalf of Reporting Manager: Name: Kathleen Eckert ------------------------------- Title: Chief Compliance Officer ------------------------------- Phone: 617-772-8500 ------------------------------- Signature, Place, and Date of Signing: /s/ Kathleen Eckert Boston, MA 2/14/06 ------------------------------- ----------------- ------------- [Signature] [City, State] [Date] Report Type (Check only one.): /X/ 13F HOLDINGS REPORT. (Check here if all holdings of this reporting manager are reported in this report.) / / 13F NOTICE. (Check here if no holdings reported are in this report, and all holdings are reported by other reporting manager(s).) / / 13F COMBINATION REPORT. (Check here if a portion of the holdings for this reporting manager are reported in this report and a portion are reported by other reporting manager(s).) List of Other Managers Reporting for this Manager: NONE FORM 13F SUMMARY PAGE Report Summary: Number of Other Included Managers: 0 -------------------- Form 13F Information Table Entry Total: 77 -------------------- Form 13F Information Table Value Total: $ 429,603 -------------------- (thousands) List of Other Included Managers: Provide a numbered list of the name(s) and Form 13F file number(s) of all institutional investment managers with respect to which this report is filed, other than the manager filing this report. NONE 1 FORM 13F INFORMATION TABLE Name of Reporting Manager: HAMBRECHT & QUIST CAPITAL MANAGEMENT LLC (SEC USE ONLY)
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8 - ------------------------- ---------------- --------- -------- ---------------------- ------------ ---------- ---------------------- VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGERS SOLE SHARED NONE - ------------------------- ---------------- --------- -------- --------- ----- ------ ------------ ---------- ------ -------- ------ ACADIA Pharmaceuticals, Inc. Common 004225108 7,746 786,368 SH Sole NA Sole Adeza Biomedical Corporation Common 006864102 4,656 221,200 SH Sole NA Sole Affymetrix, Inc. Common 00826T108 10,123 212,000 SH Sole NA Sole Align Technology, Inc. Common 016255101 8,482 1,311,000 SH Sole NA Sole Allscripts Healthcare Solutions, Inc. Common 01988P108 1,005 75,000 SH Sole NA Sole Amgen, Inc. Common 031162100 5,228 66,300 SH Sole NA Sole Ariad Pharmaceuticals, Inc. Common 04033A100 6,312 1,079,000 SH Sole NA Sole Avalon Pharmaceuticals, Inc. Common 05346P106 1,768 462,120 SH Sole NA Sole Barr Pharmaceuticals, Inc. Common 068306109 6,989 112,200 SH Sole NA Sole Barrier Therapeutics, Inc. Common 06850R108 5,720 697,600 SH Sole NA Sole Bioenvision, Inc. Common 09059N100 3,059 468,500 SH Sole NA Sole Biogen Idec Inc. Common 09062X103 2,267 50,000 SH Sole NA Sole Boston Scientific Corporation Common 101137107 2,816 115,000 SH Sole NA Sole Caraco Pharmaceutical Laboratories, Inc. Common 14075T107 2,740 305,100 SH Sole NA Sole Conor MedSystems, Inc. Common 208264101 22,045 1,147,699 SH Sole NA Sole Critical Therapeutics, Inc. Common 22674T105 3,276 456,205 SH Sole NA Sole Cubist Pharmaceuticals, Inc. Common 229678107 15,802 743,639 SH Sole NA Sole Curis, Inc. Common 231269101 101 28,000 SH Sole NA Sole Cytokinetics, Inc. Common 23282W100 2,413 368,929 SH Sole NA Sole deCODE Genetics, Inc. Common 243586104 3,108 376,232 SH Sole NA Sole DepoMed, Inc. Common 249908104 8,168 1,361,388 SH Sole NA Sole DOV Pharmaceutical, Inc. Common 259858108 3,809 259,500 SH Sole NA Sole Eclipsys Corporation Common 278856109 5,168 273,000 SH Sole NA Sole Emageon, Inc. Common 29076V109 10,782 678,124 SH Sole NA Sole Emdeon Corporation Common 290849108 5,469 646,500 SH Sole NA Sole Encysive Pharmaceuticals Inc. Common 29256X107 9,493 1,203,200 SH Sole NA Sole Endo Pharmaceuticals Holdings Common 29264F205 7,093 234,400 SH Sole NA Sole Epix Pharmaceuticals, Inc. Common 26881Q101 1,789 442,800 SH Sole NA Sole Exelixis, Inc. Common 30161Q104 7,597 806,430 SH Sole NA Sole Forest Laboratories, Inc. Common 345838106 6,285 154,500 SH Sole NA Sole Gen Probe, Inc. Common 36866T103 6,635 136,000 SH Sole NA Sole Genzyme Corporation Common 372917104 8,635 122,000 SH Sole NA Sole Gilead Sciences, Inc. Common 375558103 19,552 371,500 SH Sole NA Sole Guidant Corporation Common 401698105 3,723 57,500 SH Sole NA Sole IDEXX Laboratories, Inc. Common 45168D104 13,021 180,900 SH Sole NA Sole Imclone Systems, Inc. Common 45256B101 4,811 140,500 SH Sole NA Sole Insmed Inc. Common 457669208 2,323 1,179,400 SH Sole NA Sole Inspire Pharmaceuticals, Inc. Common 457733103 5,986 1,178,415 SH Sole NA Sole IVAX Corporation Common 465823102 4,715 150,500 SH Sole NA Sole Kosan Biosciences, Inc. Common 50064W107 3,076 692,900 SH Sole NA Sole K-V Pharmaceutical Co. CL A 482740206 3,226 156,600 SH Sole NA Sole Lexicon Genetics, Inc. Common 528872104 3,522 965,000 SH Sole NA Sole Medarex, Inc. Common 583916101 2,177 157,181 SH Sole NA Sole Medco Health Solutions, Inc. Common 58405U102 7,868 141,000 SH Sole NA Sole Medicis Pharmaceutical Corporation CL A New 584690309 1,538 48,000 SH Sole NA Sole MedImmune, Inc. Common 584699102 8,843 252,500 SH Sole NA Sole Medtronic, Inc. Common 585055106 6,477 112,500 SH Sole NA Sole MGI PHARMA, Inc. Common 552880106 5,972 348,000 SH Sole NA Sole
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8 - ------------------------- ---------------- --------- -------- ---------------------- ------------ ---------- ---------------------- VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGERS SOLE SHARED NONE - ------------------------- ---------------- --------- -------- --------- ----- ------ ------------ ---------- ------ -------- ------ Momenta Pharmaceuticals, Inc. Common 60877T100 2,018 91,559 SH Sole NA Sole Myogen, Inc. Common 62856E104 3,130 103,780 SH Sole NA Sole Myriad Genetics, Inc. Common 62855J104 6,271 301,500 SH Sole NA Sole Neurogen Corporation Common 64124E106 2,998 454,900 SH Sole NA Sole NitroMed, Inc. Common 654798503 6,361 456,000 SH Sole NA Sole Noven Pharmaceuticals, Inc. Common 670009109 6,123 404,700 SH Sole NA Sole Nuvelo, Inc. Common 67072M301 6,431 793,000 SH Sole NA Sole Orchid Cellmark, Inc. Common 68573C107 4,292 564,800 SH Sole NA Sole Orthovita, Inc. Common 68750U102 7,003 1,804,900 SH Sole NA Sole Penwest Pharmaceuticals Co. Common 709754105 2,155 110,400 SH Sole NA Sole Pharmacopeia Drug Discovery, Inc. Common 7171EP101 1,784 501,000 SH Sole NA Sole Pharmion Corporation Common 71715B409 1,125 63,300 SH Sole NA Sole Point Therapeutics, Inc. Common 730694106 2,312 670,000 SH Sole NA Sole Protein Design Labs, Inc. Common 74369L103 3,526 124,080 SH Sole NA Sole Rigel Pharmaceuticals, Inc. Common 766559603 1,282 153,300 SH Sole NA Sole Sangamo Biosciences, Inc. Common 800677106 2,401 595,700 SH Sole NA Sole Schering-Plough Corporation Common 806605101 4,343 208,300 SH Sole NA Sole Seattle Genetics, Inc. Common 812578102 5,107 1,081,900 SH Sole NA Sole Senomyx, Inc. Common 81724Q107 4,051 334,250 SH Sole NA Sole Sirna Therapeutics, Inc. Common 829669100 1,597 526,924 SH Sole NA Sole Telik, Inc. Common 87959M109 4,605 271,058 SH Sole NA Sole Tenet Healthcare Corporation Common 88033G100 4,788 625,000 SH Sole NA Sole Tercica, Inc. Common 88078L105 4,058 565,940 SH Sole NA Sole Teva Pharmaceutical Industries, Ltd. ADR ADR 881624209 12,731 296,000 SH Sole NA Sole Theravance, Inc. Common 88338T104 15,376 682,757 SH Sole NA Sole Third Wave Technologies, Inc. Common 88428W108 1,487 499,050 SH Sole NA Sole Vivus, Inc. Common 928551100 2,300 777,100 SH Sole NA Sole VNUS Medical Technologies, Inc. Common 928566108 7,789 929,458 SH Sole NA Sole ZymoGenetics, Inc. Common 98985T109 8,750 514,400 SH Sole NA Sole COLUMN TOTALS $ 429,603
-----END PRIVACY-ENHANCED MESSAGE-----